Introduction
============

Patients with chronic obstructive pulmonary disease (COPD) have limited exercise tolerance, which has been related to reduced maximal voluntary ventilation (MMV), impaired diffusion capacity of the lung and lung hyperinflation.[@b1-copd-11-2553]--[@b3-copd-11-2553] The major consequence of lung hyperinflation is the association of increased ventilatory workload and decreased inspiratory muscle pressure generating capacity, which contributes to dyspnea and poor exercise tolerance.[@b2-copd-11-2553],[@b4-copd-11-2553] Beyond the lungs, deleterious cardiovascular consequences of dynamic hyperinflation (DH) have been consistently identified in COPD patients during incremental exercise.[@b5-copd-11-2553]--[@b7-copd-11-2553] In these observations, DH was associated with reduced oxygen (O~2~) uptake efficiency slope and O~2~ pulse, which noninvasively reflect cardiac stroke volume during submaximal exercise.[@b6-copd-11-2553],[@b8-copd-11-2553],[@b9-copd-11-2553] Interestingly, lung volume reduction surgery has been shown to improve exercise tolerance through cardiac stroke volume increases.[@b10-copd-11-2553]

Along with cardiac stroke volume impairment is the concept that a contributing factor of reduced cardiac output leading to poor exercise tolerance might be the limitation to increase heart rate (HR), so called chronotropic incompetence (CI).[@b11-copd-11-2553] Chronotropic regulation involves cardiac interactions with the autonomic nervous system, which influences HR response to exercise, HR recovery and multiple components of HR variability.[@b12-copd-11-2553],[@b13-copd-11-2553] HR increases upon initiation of exercise are principally mediated by the withdrawal of cardiac parasympathetic activity, with the sympathetic contribution being manifested at a longer latency. Since vagal withdrawal with the initiation of exercise can result to an increase of 30 to 50 beats per minute (BPM) in HR, further increases are thought to be related to sympathetic activation. Recovery involves reactivation of the parasympathetic system and deactivation of sympathetic activity, causing a decline in HR. Interestingly, both impaired HR increases in proportion to the metabolic demand and HR recovery kinetics are associated with poor outcome.[@b13-copd-11-2553]

An inability of HR to increase appropriately in proportion to the metabolic demands of exercise has been termed CI, which has been originally defined as an inability to reach 80% of age-predicted maximum HR (HR~max~) or HR reserve utilization.[@b11-copd-11-2553] More adequately, the only concept that allows assessment of the entire chronotropic function is metabolic-chronotropic relationship, which takes into account individual fitness. Indeed, to ensure that reduced peak HR is not solely related to low exercise capacity, CI must be defined by the regression line between percent HR reserve and percent oxygen uptake (*V*'O~2~) reserve, ie, chronotropic-metabolic index (CMI).[@b11-copd-11-2553],[@b14-copd-11-2553] Using this approach, reduced CMI has clearly identified subgroups of patients largely dependent upon an increased HR for an increase in cardiac output during incremental exercise (HR becoming the limiting factor).[@b11-copd-11-2553] Furthermore, in heart failure patients, CI has been consistently associated with increased mortality, independently of confounding factors, such as age, gender, physical fitness, and traditional cardiovascular risk factors.[@b15-copd-11-2553],[@b16-copd-11-2553]

Mechanisms of CI are thought to be secondary to chronic overactivation of the sympathetic system and subsequent downregulation of cardiac β-adrenoreceptor densities.[@b17-copd-11-2553],[@b18-copd-11-2553] Consistent studies have shown that acute lung hyperinflation in breath-hold maneuvers can induce pulmonary vessels and heart compression leading to sympathetic activity increase.[@b19-copd-11-2553],[@b20-copd-11-2553] It is thus likely that chronic hyperinflation in COPD patients would lead to chronic sympathetic overactivation and blunted cardiac chronotropic response.[@b21-copd-11-2553],[@b22-copd-11-2553] Recent findings supported that CI is common in patients with severe COPD and may be improved after lung volume reduction surgery.[@b23-copd-11-2553],[@b24-copd-11-2553] CI was also found as an independent and powerful outcome predictor in severe COPD patients.[@b25-copd-11-2553] Of note, whether CI as evaluated by CMI was related to lung hyperinflation has not been reported previously. Our aim was thus to test whether CI could be related to lung DH in exercising patients. We also aimed to determine the different factors, such as breathing pattern, DH and CI, which can influence exercise intolerance in COPD patients.

Patients and methods
====================

Patients
--------

This study was conducted in accordance with the amended Declaration of Helsinki (<http://www.wma.net/en/30publications/10policies/b3/>). The Institutional Review Board of Lille University Hospital (Lille, France) approved this study (2014-0111-b), which only included patients referred to our department for routine functional evaluation. Written informed consent was obtained from all patients. We prospectively enrolled all consecutive patients suffering from COPD, defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.[@b26-copd-11-2553] The diagnosis of COPD was confirmed by forced spirometry, when the patient was considered clinically stable. All the procedures and their risks were explained to the patients, who gave their verbal informed consent to enter the study. Pulmonary function testing as well as exercise studies had been undertaken for clinical reasons at the request of the patients' clinicians.

Inclusion and exclusion criteria
--------------------------------

Caucasian subjects, either current or former smokers, with spirometrically confirmed COPD in GOLD stages were included. They had to have been free of COPD exacerbations during the last 3 months prior to inclusion. Patients with a history of left ventricular disease, left ventricular ejection fraction \<45%, severe pulmonary hypertension (mean pulmonary artery pressure (PAP) \>35 mmHg) were excluded. Patients treated for hypertension with blood pressure \>160/90 mmHg, with arrhythmias, with significant coronary artery disease or using β-blockers were also excluded. None of the subjects had noninvasive positive-pressure ventilation support or long-term ambulatory O^2^ treatment.

Pulmonary function
------------------

Standard forced expiratory spirometry (forced expiratory volume in the first second (FEV~1~) and forced expiratory vital capacity (FVC)) and body plethysmography (residual volume (RV), functional residual capacity (FRC), total lung capacity (TLC)), and diffusing capacity of the lung for carbon monoxide (*D*~L,CO~) were performed (MasterScreen™ body plethysmograph, Viasys, France) using European and American Thoracic Society guidelines.[@b27-copd-11-2553]

Cardiopulmonary testing
-----------------------

Cardiopulmonary exercise testing was performed according to standardized procedures using an electromagnetic braked cycle ergometer.[@b28-copd-11-2553] Exercise protocol involved an initial 2 minutes of rest, followed by 2 minutes of unloaded cycling with a progressive increment every minutes (10 W·m^−1^) until exhaustion at a pedaling frequency of 60--65 rpm. Subjects were continuously monitored by 12-lead electrocardiogram (Cardiosoft, CareFusion, France). Blood pressure assessed by sphygmomanometry was recorded every 2 minutes. Arterial blood (240 μL) was sampled at rest and at peak exercise and immediately analyzed using a blood gas analyzer/co-oximeter (ABL700, Radiometer, France).

Subjects respired through an oro-nasal mask (Hans Rudolf 7450 SeriesV2™ Mask, CareFusion, France). Breath-by-breath cardiopulmonary data (Vyntus, CareFusion, France) were measured at rest, warm up and incremental exercise testing. Before each test, O~2~ and carbon dioxide (CO~2~) analyzers and flow mass sensor were calibrated using available precision gas mixture and a 3-L syringe, respectively. Minute ventilation (*V*'~E~), *V*'O~2~, carbon dioxide output (*V*'CO~2~) were recorded as concurrent 10 seconds moving averages, as was determined ventilation anaerobic threshold (AT) by the V-slope method. Ventilatory reserve was calculated as (MVV − peak *V*'~E~)/MVV \* 100 where MVV is maximal voluntary ventilation estimated as FEV~1~ multiplied by 35. Peak values were averaged over the last 30 seconds of exercise. Patient effort was considered to be maximal if two of the following occurred: predicted maximal work is achieved, predicted maximal HR is achieved, *V*'~E~/*V*'O~2~ \>45, lactate level \>6 mmol·L^−1^, RER \>1.10 and pH drop \>0.06, as recommended by the ATS/ACCP.[@b28-copd-11-2553] At peak exercise, subjects assessed Borg-perceived exertion ratings for both respiratory and leg discomfort. During the study period, mean values between qualified replicate tests performed weekly on control subjects were 5.1%±4.2%, 5.4%±3.2%, 6.1%±2.2%, for peak *V*'O~2~, *V*'CO~2~ and *V*'~E~, respectively.

Peak oxygen pulse (O~2~ pulse) was calculated and was expressed in mL per beat and as percentage of predicted value by dividing the predicted peak *V*'O~2~ by predicted peak HR. *V*'~E~/*V*'CO~2~ slope was calculated off-line as a linear regression function using 10-s averaged values and excluding the non-linear part of the relationship after the respiratory compensation point (where nonlinear rise in *V*'~E~ occurred relative to *V*'CO~2~ in the presence of decrease of end-tidal pressure of CO~2~). The *V*'O~2~ efficiency slope (OUES) describes the relationship between *V*'O~2~ and *V*'~E~ during incremental exercise, via a log transformation of *V*'~E~.[@b29-copd-11-2553] OUES was expressed as the slope of the linear relationship of log~10~ *V*'~E~ to *V*'O~2~ (L·min^−1^) using *V*'O~2~ (L·min^−1^) = m (log~10~ *V*'E) + b, where m=OUES. Double-product (mmHg·bpm) was calculated as the product of systolic blood pressure by the HR.

DH
--

Changes in operational lung volumes were evaluated from measurements of inspiratory capacity (IC).[@b1-copd-11-2553]--[@b3-copd-11-2553] End-expiratory lung volume (EELV) was assessed from IC maneuvers at rest, every 2 minutes during exercise and at peak exercise (Vyntus). In these maneuvers, after EELV was observed to be stable over 3--4 breaths, subjects were instructed to inspire maximally to TLC. For each measurement, EELV was calculated as resting TLC minus IC, using the plethysmographic TLC value. Dynamic IC (IC~dyn~) was defined as resting IC minus IC at peak exercise. DH as dichotomous variable was performed from optimal knot of IC~dyn~ (see section "Statistical analysis", "Results", and [Figure 1](#f1-copd-11-2553){ref-type="fig"}). An inflection in tidal volume (*V*~T~) relative to *V*'~E~ (expressed as % peak *V*'~E~) was determined in each patient during exercise.

CMI
---

Chronotropic index was defined as an index of maximal predicted HR reserve achieved.[@b11-copd-11-2553] The percentage of HR reserve used at peak exercise referred to \[(HR~stage~ − HR~rest~)/(220 − age in years − HR~rest~)\] \* 100, where HR is heart rate. For any given stage of exercise, the percentage of *V*'O~2~ reserve used referred to \[(*V*'O~2\ stage~ − *V*'O~2\ rest~)/(*V*'O~2\ peak~ − *V*'O~2\ rest~)\] \* 100. CMI was calculated off-line as the regression line slope between percent HR reserve and percent *V*'O~2~ reserve. A patient was referred to as having CI if the resulting slope index was \<0.75 and HR~max~ \<80%.[@b11-copd-11-2553],[@b14-copd-11-2553]

Statistical analysis
--------------------

The statistical analyses were performed with SAS software (SAS Institute Inc., Cary, NC, USA; version 9.3). A two-sided significance level of 0.05 was chosen for all tests. Descriptive statistics, with tests of normality (Shapiro--Wilk test) for values showed free distributions. Values were expressed as medians with interquartile ranges (IQR). Patients were divided according to GOLD classification.[@b30-copd-11-2553] Nonparametric analysis (Kruskal--Wallis test) was used to test for differences between classes. Post hoc comparisons were determined by Wilcoxon test with Bonferroni correction. Relationships between quantitative variables were assessed by the Spearman's correlation coefficient (r). Bivariate comparisons for categorical variables were performed with Chi-squared test (with Fisher correction as appropriate).

Locally estimated scatterplot smoother SAS procedure showed a broken-line trend between CMI or HR~max~ and IC~dyn~ changes. Linear mixed model procedure was used to analyze the change of CMI and HR~max~ versus a broken function of IC~dyn~ that took 0 before the knot and subject's IC~dyn~ after the knot; the knot position was fixed by the smallest Akaike information criterion (AIC) using Gauss--Newton method.[@b31-copd-11-2553],[@b32-copd-11-2553] Thus, mean and 95% confidence interval of optimal knot, intercept (no change), and slope (increase) were estimated by nonlinear mixed model. As these two variables are used interchangeably in the literature to define CI, we took the middle of the overlap area of the IC~dyn~ knot from these two relationships. IC~dyn~ converted to DH as dichotomous variables indicating IC~dyn~ \< optimal knot (DH=1) or IC~dyn~ ≥ optimal knot (DH=0). The association between CI and DH with covariables (age, body mass index (BMI), TLC, IC/TLC, RV/TLC, GOLD stage) was estimated as an odds ratio (OR) and 95% confidence intervals by using multivariate logistic regression analyses.

Results
=======

We included 47 consecutive stable COPD patients (age 55 (49; 61) years, BMI 26 (22; 30), female n=14). All patients were maximally treated with bronchodilators. At study entry, patients were receiving inhaled steroids (75%), long-acting β~2~-agonists (75%) and tiotropium (65%); all of them were active or ex-smokers. Overall, a wide range of airflow obstruction (FEV~1~/FVC from 26% to 69%; 56 (50; 64) %), static hyperinflation (IC/TLC from 24% to 61% predicted; 40 (36; 46) % predicted), diffusing capacity (*D*~L,CO~ from 17% to 98% predicted; 73 (49; 85) % predicted) was found. Nine out of 42 patients (21%) suffered from well-controlled arterial hypertension and were on diuretics (72%), ACE-inhibitors (52%), calcium-antagonists (36%) to control the disease.

According to objective ATS/ACCP criteria, exercise was considered maximal in all patients.[@b28-copd-11-2553] Mean peak workload and *V*'O~2~ was 90 (65; 95) watts (range 55--170 watts) and 18.5 (15.6; 22.6) mL·kg^−1^·min^−1^ (67 (61; 78) % predicted), respectively. AT *V*'O~2~ was 12.1 (11.0; 14.4) mL·kg^−1^·min^−1^. Peak *V*~T~ to FEV~1~ ratio was 37 (30; 48) % and plateau of *V*~T~ increase occurred at 70.8 (61.1; 77.8) % of maximum *V*'~E~. Breathing reserve at peak exercise was reduced (24 (3; 33) %). IC~dyn~ change measured from rest to peak exercise was −0.39 (−0.67; −0.07) L and peak EELV (% TLC) was 64 (56; 72) %. HR~max~ was 134 (119; 150) bpm (80 (73; 88) % predicted) with HR reserve utilization of 60 (43; 76) %. Peak O~2~ pulse was 10.2 (8.6; 12.4) mL·bpm^−1^ (84 (71; 97) % predicted). Peak systemic arterial partial pressure of O~2~ (*Pa*,O~2~) and CO~2~ (*Pa*,CO~2~) were 91 (70; 99) and 39 (35; 41) mmHg, respectively. Arterial lactate was 5.6 (4.7; 7.0) mmol·L^−1^ at peak exercise.

Functional characteristics of patients classified by GOLD scaling system are shown in [Table 1](#t1-copd-11-2553){ref-type="table"}. Static hyperinflation significantly decreased incrementally from stage I to stage III--IV among baseline pulmonary function parameters ([Table 1](#t1-copd-11-2553){ref-type="table"}). [Tables 2](#t2-copd-11-2553){ref-type="table"}[](#t3-copd-11-2553){ref-type="table"}--[4](#t4-copd-11-2553){ref-type="table"} (main features of CPET, ventilatory and cardiovascular response details, respectively) display all results and significant differences of medians of exercise parameters between each group (GOLD stage I, stage II and stage III--IV) after adjustments. Peak *V*'O~2~ (% of predicted values) was not significantly different between GOLD stages ([Table 2](#t2-copd-11-2553){ref-type="table"}). At peak exercise ([Table 3](#t3-copd-11-2553){ref-type="table"}), EELV (% TLC), *V*~D~/*V*~T~(%) and *Pa*,CO~2~ significantly increased incrementally with patient's COPD severity. IC~dyn~ significantly decreased incrementally with patient's COPD severity ([Table 3](#t3-copd-11-2553){ref-type="table"}).

The nonlinear procedure established between IC~dyn~ change and CMI ([Figure 1A](#f1-copd-11-2553){ref-type="fig"}) or HR~max~ ([Figure 1B](#f1-copd-11-2553){ref-type="fig"}) has converged to broken-line models. The best fit, which was defined by the smallest AIC, allowed us to obtain the values of the following knots IC~dyn~ (mean ± standard error): −0.28±0.1 L and −0.39±0.08 L, respectively. The middle of the overlap area allowed us to determine the DH threshold with IC~dyn~ change equal to −0.34 L.

The prevalence of DH was higher in GOLD III--IV patients than in GOLD I--II patients ([Table 5](#t5-copd-11-2553){ref-type="table"}). Patients with lung hyperinflation had more CI than patients without DH ([Table 5](#t5-copd-11-2553){ref-type="table"}). CI status was not related to GOLD score (*P*=0.1).

The logistic regression that analyzed the association between CI (outcome) and DH showed a strong relationship (OR \[confidence interval 95%\]) 20 \[4.4--91.9\] that was confirmed by multivariate analysis taking into account the following covariates: age, BMI, TLC, CI/TLC, RV/TLC and GOLD stage ([Table 6](#t6-copd-11-2553){ref-type="table"}).

Discussion
==========

A new finding of this study is that lung hyperinflation in COPD patients is associated with impaired metabolic-chronotropic relationship, so-called CI, which may present as a limiting factor of exercise tolerance.

In our study, both static and dynamic lung volume measurements were performed to assess lung hyperinflation in COPD patients. Among baseline pulmonary function parameters, we used IC/TLC ratio as a static hyperinflation-derived variable reflecting mechanical inspiratory constraint.[@b1-copd-11-2553]--[@b3-copd-11-2553] We found that over a wide range of airflow, IC/TLC decreased incrementally with FEV~1~/FVC obstruction. Such relationship was also observed with RV/TLC, which increased incrementally with FEV~1~/FVC. Next, we established exercise-induced DH by measuring IC~dyn~.[@b1-copd-11-2553]--[@b3-copd-11-2553] IC~dyn~ significantly decreased incrementally with patient's GOLD score severity. DH was associated with increased *V*~T~ constraint as *V*~T~/*V*'~E~ inflection point expressed as peak *V*'~E~ percent was decreased incrementally with patient's COPD severity. DH was accompanied with poor cardiovascular response, which was evaluated in our study by noninvasive surrogate markers, such as OUES and O~2~ pulse.[@b5-copd-11-2553]--[@b7-copd-11-2553] O~2~ pulse, a noninvasive measure of stroke volume, requires assumption that the arteriovenous O~2~ content difference remains constant during exercise. Physiologically, arterial O~2~ content can be altered by hemoglobin availability, arterial blood oxygenation and peripheral O~2~ extraction.[@b33-copd-11-2553] In our series of COPD patients, hemoglobin concentration and calculated arterial content were within the normal ranges. Furthermore, whether O~2~ extraction was normal or reduced in our patients, these changes may not account for O~2~ pulse reduction, since a lower O~2~ extraction would actually increase O~2~ pulse.[@b6-copd-11-2553],[@b10-copd-11-2553]

Beside the negative effects of abnormal ventilatory mechanics on cardiac stroke volume, CI can also prevent the cardiovascular system from reaching its physiological limits before maximal exercise.[@b11-copd-11-2553] In healthy humans, HR increases virtually instantaneously upon the initiation of exercise. Involvement of a reduction in cardiac parasympathetic activity has been demonstrated in human studies showing that atropine can significantly attenuate the initial increase in HR in a variety of exercise conditions. In contrast, the magnitude of HR increase at the onset of exercise is not diminished by prior β-adrenergic blockade, implying a minimal influence of sympathetic activity at this time.[@b34-copd-11-2553],[@b35-copd-11-2553] Thereafter, there is an approximately linear relationship between HR and *V*'O~2~ during incremental dynamic exercise. At moderate-to-elevated exercise intensities β-adrenergic blockade significantly attenuates the size of the HR response, thus suggesting a key role for heightened sympathetic nervous system and elevated catecholamine levels in the circulation.[@b34-copd-11-2553]--[@b36-copd-11-2553] At immediate cessation of exercise, HR abruptly declines, which is typically followed by a more gradual decline of HR over minutes depending on exercise conditions. Initial HR recovery is related to rapid restoration of cardiac parasympathetic activity, since it is virtually abolished by atropine administration, but unaffected by β-adrenergic blockade.[@b37-copd-11-2553]

Blunted HR response is the primary cause of or a significant contributor to severe, symptomatic exercise intolerance in heart failure patients.[@b15-copd-11-2553],[@b16-copd-11-2553] Mechanisms of CI have been related to overstimulation of the sympathetic system, which induces downregulation of β-receptors and their desensitization in the presence of increased circulating catecholamine levels.[@b17-copd-11-2553],[@b18-copd-11-2553] In COPD patients, a striking elevation of sympathetic tone has been demonstrated and might thus provide a link between COPD and CI. Hypoxemia, chemoreflexes, impaired baroreflex sensitivity, muscle ergoreflex and lung hyperinflation are important factors contributing to neurohumoral activation in COPD.[@b20-copd-11-2553],[@b38-copd-11-2553] In normal subjects, sympathetic nerve firings are synchronized with central inspiratory motor activity and increase in lung volume during inspiration activates pulmonary vagal afferents that in turn inhibit sympathetic nerve discharge.[@b20-copd-11-2553],[@b38-copd-11-2553] The relative magnitude of these two opposing mechanisms determines the net effect of respiratory modulation of sympathetic nerve activity, which is in favor of sympathetic activation in COPD patients.[@b21-copd-11-2553],[@b22-copd-11-2553]

Although lung hyperinflation may induce sympathetic overactivation in COPD patients, whether DH would lead to CI during submaximal exercise has not been previously tested. In normal subjects, CI has been most commonly diagnosed when HR fails to reach 80%--85% of the HR~max~.[@b11-copd-11-2553] However, before one concludes that a patient has CI, it is important to consider the patient's level of effort.[@b14-copd-11-2553] Whether attenuated HR in response to incremental exercise is related to low effort level or CI represents a major issue in this context. Hence, in order to more objectively evaluate CI, the relationship between HR and *V*'O~2~ during exercise should be measured.[@b11-copd-11-2553],[@b14-copd-11-2553] In this approach, the metabolic-chronotropic relationship is calculated from the ratio of the HR reserve to the metabolic reserve during submaximal exercise.[@b39-copd-11-2553],[@b40-copd-11-2553] If the assumption on which percentage of HR reserve equal *V*'O~2~ reserve is achieved in normal adults, a relationship slope less than 0.75--0.8 is considered indicative of CI in chronic heart disease patients.[@b39-copd-11-2553],[@b40-copd-11-2553] In our study, this metabolic-chronotropic relationship approach allowed us to define an association between CI and DH, which was further characterized by broken-line trend analysis with a reduced IC~dyn~ of 0.34 L as a threshold level for CI.

In conclusion, we have shown that CI evaluated by the metabolic-chronotropic relationship is highly prevalent in a cohort of COPD patients. Adding evaluation of CI to standard pulmonary function parameters at rest and during incremental exercise allows to determine the level of lung hyperinflation as a potential mechanism of attenuated HR response.
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![Relationship between dynamic inspiratory capacity (IC~dyn~) changes from rest to peak with chronotropic-metabolic index and percentage of age-predicted maximum heart rate (HR~max~), (**A** and **B**), respectively.\
**Notes:** Global Initiative for Chronic Obstructive Lung Disease stages (stage 1: half-full dots; stage 2: empty squares; stage 3 and 4: filled triangles). The broken-line trend is represented by the black solid lines.](copd-11-2553Fig1){#f1-copd-11-2553}

###### 

Subject characteristics

  GOLD stage                       Stage I                                                                                                        Stage II                                                                                                      Stage III--IV                                                                                                 *P*-value
  -------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------
  Age, years                       53.5 (49; 56)                                                                                                  60 (54; 64)[‡](#tfn2-copd-11-2553){ref-type="table-fn"}                                                       49 (44; 56)[‡](#tfn2-copd-11-2553){ref-type="table-fn"}                                                       **0.031**
  BMI, kg·m^−2^                    26.0 (23.8; 26.4)                                                                                              27.8 (22.8; 30.7)                                                                                             21.9 (18.9; 29.1)                                                                                             0.224
  Gender, M/F                      4/2                                                                                                            22/4                                                                                                          7/8                                                                                                           **0.028**
  Smoking status, % current        50                                                                                                             40                                                                                                            20                                                                                                            0.238
  Smoking, pack-year               30 (30; 40)                                                                                                    27.5 (16.5; 40)                                                                                               42.5 (25; 61)                                                                                                 0.279
  **Lung function test**                                                                                                                                                                                                                                                                                                                                                      
  FEV~1~ L                         3.2 (3.0; 3.4)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[\#](#tfn2-copd-11-2553){ref-type="table-fn"}      2.1 (1.8; 2.6)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      1.4 (1.2; 1.7)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      \<**0.001**
  FEV~1~ % predicted               0.88 (0.83; 0.94)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[\#](#tfn2-copd-11-2553){ref-type="table-fn"}   0.66 (0.59; 0.72)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}   0.45 (0.34; 0.48)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  FVC, L                           4.9 (4.4; 5.7)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[\#](#tfn2-copd-11-2553){ref-type="table-fn"}      3.8 (3.1; 4.3)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      3.1 (2.7; 3.6)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      \<**0.001**
  FEV~1~/FVC, %                    67.2 (64.8; 68.4)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[\#](#tfn2-copd-11-2553){ref-type="table-fn"}   58.8 (54.1; 63.7)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}   47.8 (32.6; 54.5)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  IC, L                            3.2 (3.0; 4.4)[\#](#tfn2-copd-11-2553){ref-type="table-fn"}                                                    2.8 (2.4; 3.3)[‡](#tfn2-copd-11-2553){ref-type="table-fn"}                                                    2.1 (1.9; 2.7)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      **0.001**
  TLC, L                           7.4 (6.7; 8.1)                                                                                                 6.1 (5.6; 7.3)                                                                                                6.5 (5.8; 7.5)                                                                                                0.187
  FRC, L                           3.7 (3.6; 3.9)                                                                                                 3.5 (3.0; 4.6)                                                                                                4.5 (3.5; 4.8)                                                                                                0.248
  IC/TLC                           45.7 (40.8; 53.8)[\#](#tfn2-copd-11-2553){ref-type="table-fn"}                                                 41.5 (38.8; 47.1)[‡](#tfn2-copd-11-2553){ref-type="table-fn"}                                                 35.6 (29.4; 39.9)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  RV, L                            2.4 (2.3; 2.9)[\#](#tfn2-copd-11-2553){ref-type="table-fn"}                                                    2.8 (1.8; 3.4)                                                                                                3.4 (2.7; 4.0)[\#](#tfn2-copd-11-2553){ref-type="table-fn"}                                                   **0.012**
  RV/TLC, %                        98 (86; 100)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[\#](#tfn2-copd-11-2553){ref-type="table-fn"}        114.5 (104; 123)[\*](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}    145 (136; 160)[\#](#tfn2-copd-11-2553){ref-type="table-fn"},[‡](#tfn2-copd-11-2553){ref-type="table-fn"}      \<**0.001**
  *D*~L,CO~, mL·min^−1^·mmHg^−1^   23.0 (15.2; 26.7)                                                                                              19.8 (14.4; 24.3)                                                                                             11.6 (9.6; 15.5)                                                                                              **0.032**
  *D*~L,CO~ % predicted            81.5 (59; 88)                                                                                                  75 (51; 85)                                                                                                   48 (38; 62)                                                                                                   **0.033**

**Notes:** Data are presented as median (interquartile range).

Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index; FEV~1~, forced expiratory volume in the first second; FVC, forced expiratory vital capacity; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual capacity; RV, residual volume; *D*~L,CO~, diffusing capacity of the lung for carbon monoxide; M, male; F, female.

###### 

Cardiopulmonary exercise testing (peak values, except AT)

  GOLD stage                       Stage I                                                                                                        Stage II                                                         Stage III--IV                                                                                           *P*-value
  -------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------
  Workload, W                      97.5 (95; 150)[\#](#tfn5-copd-11-2553){ref-type="table-fn"}                                                    90 (80; 100)[‡](#tfn5-copd-11-2553){ref-type="table-fn"}         65 (60; 85)[\#](#tfn5-copd-11-2553){ref-type="table-fn"},[‡](#tfn5-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  *V*'O~2~, mL·kg^−1^·min^−1^      24.3 (23.6; 25.2)[\#](#tfn5-copd-11-2553){ref-type="table-fn"}                                                 18.5 (15.5; 21.8)                                                17.5 (15.4; 19.1)[\#](#tfn5-copd-11-2553){ref-type="table-fn"}                                          **0.035**
  *V*'O~2~, % predicted            77.4 (62.8; 80.9)                                                                                              70.0 (55.0; 80.0)                                                64.0 (61.0; 68.0)                                                                                       0.215
  AT *V*'O~2~, mL·kg^−1^·min^−1^   16.0 (15.0; 16.6)[\*](#tfn5-copd-11-2553){ref-type="table-fn"},[\#](#tfn5-copd-11-2553){ref-type="table-fn"}   12.1 (10.6; 14.1)[\*](#tfn5-copd-11-2553){ref-type="table-fn"}   12.0 (11.0; 13.4)[\#](#tfn5-copd-11-2553){ref-type="table-fn"}                                          **0.033**
  RER                              1.2 (1.0; 1.3)                                                                                                 1.2 (1.1; 1.2)                                                   1.2 (1.1; 1.2)                                                                                          0.859
  Arterial lactate, mmol·L^−1^     7.6 (5.7; 9.2)                                                                                                 5.7 (4.8; 7.3)                                                   5.5 (4.3; 6.4)                                                                                          **0.036**
  Borg dyspnea score               4 (3; 7)                                                                                                       4 (3; 5)                                                         3 (3; 5)                                                                                                0.865
  Borg leg effort score            4 (4; 7)                                                                                                       4 (3; 5)                                                         3 (2; 5)                                                                                                0.314

**Notes:** Data are presented as median (interquartile range).

Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** AT, anaerobic threshold; GOLD, Global Initiative for Chronic Obstructive Lung Disease; *V*'O~2~, oxygen uptake; RER, respiratory exchange ratio.

###### 

Ventilatory response during submaximal exercise (peak values, except *V*~T~/*V*'~E~ inflexion point)

  GOLD stage                                        Stage I                                                                                                        Stage II                                                                                                      Stage III--IV                                                                                                    *P*-value
  ------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------
  *f*~R~, breaths·min^−1^                           31 (23; 41)                                                                                                    31 (27; 38)                                                                                                   34 (30; 38)                                                                                                      0.655
  *V*~T~, L                                         2.3 (1.8; 3.3)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                                    1.8 (1.6; 2.0)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                    1.5 (1.1; 1.6)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}         **0.001**
  *V*~T~/FEV~1~, %                                  74.9 (59.5; 91.0)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                                 83.6 (74.6; 91.0)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                 105.0 (85.6; 117.2)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}    **0.003**
  *V*~T~/FVC, %                                     49.5 (40.7; 57.3)                                                                                              48.4 (45.2; 51.1)                                                                                             46.3 (38.5; 50.2)                                                                                                0.649
  *V*'~E~, L·min^−1^                                76.5 (64; 88)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[\#](#tfn8-copd-11-2553){ref-type="table-fn"}       54.5 (48; 64)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}       48 (37; 53)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}            \<**0.001**
  *V*'~E~ reserve, % predicted                      33.9 (11.7; 44.9)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                                 28.0 (21.8; 34.4)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                 2.7 (−10.5; 16.6)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}      \<**0.001**
  *V*~T~/*V*'~E~ inflection point, % peak *V*'~E~   52.5 (46; 61)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[\#](#tfn8-copd-11-2553){ref-type="table-fn"}       40 (32; 50)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}         30 (26; 32)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}            \<**0.001**
  IC~dyn~, L                                        −0.08 (−0.14; 0.11)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                               220.38 (−0.52; 0)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                 −0.67 (−0.95; −0.35)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  EELV/TLC, %                                       53 (49; 58)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                                       61 (54; 70)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                       70 (68; 79)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}            \<**0.001**
  **Gas exchange**                                                                                                                                                                                                                                                                                                                                                                                
  *V*~D~/*V*~T~, %                                  32 (31; 35)[\#](#tfn8-copd-11-2553){ref-type="table-fn"}                                                       37 (31; 40)[‡](#tfn8-copd-11-2553){ref-type="table-fn"}                                                       45 (38; 51)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}            **0.004**
  *P*a,O~2~, mmHg                                   99.8 (98; 101)                                                                                                 93.5 (80.7; 99)                                                                                               86 (60; 93)                                                                                                      0.065
  *P*a,CO~2~, mmHg                                  33.1 (27.0; 35.0)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[\#](#tfn8-copd-11-2553){ref-type="table-fn"}   38.5 (36.0; 40.6)[\*](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}   41.4 (40.7; 45.0)[\#](#tfn8-copd-11-2553){ref-type="table-fn"},[‡](#tfn8-copd-11-2553){ref-type="table-fn"}      \<**0.001**

**Notes:** Data are presented as median (interquartile range).

Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; *f*~R~, breathing frequency; *V*~T~, tidal volume; FEV~1~, forced expiratory volume in the first second; FVC, forced expiratory vital capacity; *V'*~E~, minute ventilation; IC~dyn~, dynamic inspiratory capacity; EELV, end-expiratory lung volume; TLC, total lung capacity; *V*~D~, dead volume; *Pa*,O~2~, arterial partial pressure of oxygen; *Pa*,CO~2~, arterial partial pressure of carbon dioxide.

###### 

Cardiovascular response during submaximal exercise (peak values, except recovery)

  GOLD stage                              Stage I                                                                 Stage II                                                               Stage III--IV                                                                                                         *P*-value
  --------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------
  HR, beat·min^−1^                        149 (142; 162)                                                          130 (113; 150)                                                         133 (122; 140)                                                                                                        0.074
  HR peak-rest, beat·min^−1^              60 (54; 71)                                                             42.5 (32; 67)                                                          42 (28; 61)                                                                                                           0.102
  HR~max~, %                              88.2 (83.3; 94.7)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}         79.2 (73.4; 90.6)                                                      78.8 (70.7; 83.2)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}                                                       **0.042**
  HR reserve use, %                       76.3 (67.5; 87.3)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}         55.0 (41.3; 80.6)                                                      52.5 (42.6; 63.8)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}                                                       **0.032**
  Chronotropic-metabolic index            0.68 (0.61; 0.73)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}         0.58 (0.47; 0.75)                                                      0.47 (0.39; 0.60)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}                                                       **0.027**
  O~2~ pulse, mL·beat^−1^                 11.7 (10.5; 12.4)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}         10.8 (10.1; 13.9)[‡](#tfn11-copd-11-2553){ref-type="table-fn"}         8.3 (7.3; 9.7)[\#](#tfn11-copd-11-2553){ref-type="table-fn"},[‡](#tfn11-copd-11-2553){ref-type="table-fn"}            \<**0.001**
  O~2~ pulse, % predicted                 95.5 (88.0; 104.0)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}        86.0 (74.0; 99.0)[‡](#tfn11-copd-11-2553){ref-type="table-fn"}         77.0 (65.0; 82.0)[\#](#tfn11-copd-11-2553){ref-type="table-fn"},[‡](#tfn11-copd-11-2553){ref-type="table-fn"}         **0.005**
  OUES, mL·min^−1^                        1 548 (1 344; 1 988)                                                    1 701 (1 467; 1 988)                                                   1 321 (1 138; 1 937)                                                                                                  0.188
  *V*'~E~/*V*'CO~2~ slope                 26.1 (23.8; 30.3)                                                       30.2 (26.9; 33.5)                                                      32.0 (29.0; 37.4)                                                                                                     0.079
  Mean arterial pressure, mmHg            125.3 (120.0; 133.0)                                                    123.7 (103.5; 135.2)                                                   117.0 (111.7; 125.0)                                                                                                  0.537
  Double product, mmHg·beat·min^−1^       29 523 (28 120; 31 266)[\#](#tfn11-copd-11-2553){ref-type="table-fn"}   25 619 (23 471; 29 539)[‡](#tfn11-copd-11-2553){ref-type="table-fn"}   20 295 (19 380; 24 024)[\#](#tfn11-copd-11-2553){ref-type="table-fn"},[‡](#tfn11-copd-11-2553){ref-type="table-fn"}   \<**0.001**
  **Post-exercise heart rate recovery**                                                                                                                                                                                                                                                                        
  HR recovery at 1 min, beat·min^−1^      17.5 (13; 18)                                                           10 (3; 19)                                                             13 (6; 20)                                                                                                            0.636
  HR recovery at 3 min, beat·min^−1^      41 (31; 49)                                                             28.5 (20; 35)                                                          27 (19; 36)                                                                                                           0.262

**Notes:** Data are presented as median (interquartile range).

Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart rate; HR~max~, age predicated maximum heart rate; min, minute; O~2~, oxygen; OUES, oxygen uptake efficiency slope; *V'*~E~, minute ventilation; *V'*CO~2~, carbon dioxide output.

###### 

Relationships between dynamic hyperinflation, GOLD stage and chronotropic incompetence

  Group patients                 No hyperinflation[\*](#tfn13-copd-11-2553){ref-type="table-fn"}   Hyperinflation[\*](#tfn13-copd-11-2553){ref-type="table-fn"}   *P*-value[\*\*](#tfn14-copd-11-2553){ref-type="table-fn"}
  ------------------------------ ----------------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------
  GOLD                                                                                                                                                            **0.019**
   I--II                         18                                                                14                                                             
   III--IV                       3                                                                 12                                                             
  Chronotropic incompetence, %   14.3                                                              76.9                                                           \<**0.0001**

**Notes:**

Defined by an IC~dyn~ \<−0.34 L;

*P*-values obtained by Fisher exact test. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC~dyn~, dynamic inspiratory capacity.

###### 

Multivariate analysis of chronotropic incompetence

  Variables                       OR (95% confidence interval)
  ------------------------------- ------------------------------------------------------------------------
  Dynamic hyperinflation status   **25 (3.5--191.6)[\*](#tfn16-copd-11-2553){ref-type="table-fn"}**
  Age                             **1.094 (1.008--1.187)[\*](#tfn16-copd-11-2553){ref-type="table-fn"}**
  BMI                             0.952 (0.826--1.098)
  TLC                             0.676 (0.342--1.336)
  IC/TLC                          0.956 (0.849--1.076)
  RV/TLC                          1.004 (0.970--1.039)
  GOLD stage                      1.056 (0.088--12.634)

**Notes:**

*P*-values \<0.05. Bold values represent the significant results.

**Abbreviations:** OR, odds ratio; BMI, body mass index; TLC, total lung capacity; IC, inspiratory capacity; RV, residual volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
